sargramostim + temozolomide

Sargramostim + temozolomide is an investigational combination therapy consisting of sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), and temozolomide, an oral alkylating agent. Sargramostim acts as a cytokine that stimulates the production and function of white blood cells by binding to the granulocyte-macrophage colony stimulating factor receptor, thereby enhancing immune cell recovery after chemotherapy or bone marrow transplantation. Temozolomide is a DNA-alkylating small molecule chemotherapeutic that induces cytotoxicity in rapidly dividing tumor cells by methylating DNA at the O6 and N7 positions of guanine. This combination has been studied primarily in oncology settings such as high-risk neuroblastoma (often with additional agents) and glioblastoma, aiming to leverage both direct antitumor effects from temozolomide and immune system support or modulation from sargramostim[1][2][3][5][6].